Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017

References

• Di Pasquale A, Bonanni P, Garçon N, Stanberry L, El-Hodhod M, Tavares Da Silva F. Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine. 2016;34(52):6672–80. doi:10.1016/j.vaccine.2016.10.039.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Adverse events following immunization: real causality and myths. Expert Opin Drug Saf. 2016 Jun;15(6):825–35. doi:10.1517/14740338.2016.1167869.
   PubMed Web of Science ®Google Scholar
• Chen RT, Davis RL. Rhodes PH Special methodological issues in pharmacoepidemiology studies of vaccine safety. Pharmacoepidemiology. 4th ed. John Wiley & Sons, Ltd. 2007. 455–85. doi:10.1002/9780470059876.ch30.
   Google Scholar
• Shimabukuro T, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–405. doi:10.1016/j.vaccine.2015.07.035.
   PubMed Web of Science ®Google Scholar
• Haider N, Mazhar F. Factors associated with underreporting of adverse drug reactions by nurses: a narrative literature review. Saudi J Health Sci. 2017;6(2):71. doi:10.4103/sjhs.sjhs_37_17.
   Google Scholar
• Hoffman BL, Felter EM, Chu KH, Shensa A, Hermann C, Wolynn T, Williams D, Primack BA. It’s not all about autism: the emerging landscape of anti-vaccination sentiment on Facebook. Vaccine. 2019 Apr 10;37(16):2216–23. doi:10.1016/j.vaccine.2019.03.003.
   PubMed Web of Science ®Google Scholar
• Varallo F, Guimarães S, Abjaude S, Mastroianni P. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Escola Enfermagem USP. 2014;48(4):739–47. doi:10.1590/S0080-623420140000400023.
   PubMed Web of Science ®Google Scholar
• WHO. Causality Assessment of an adverse event following immunization (AEFI). User manual for the revised WHO classification. [accessed 2018 Jan]. http://apps.who.int/iris/bitstream/handle/10665/259959/9789241513654-eng.pdf?sequence=1.
   Google Scholar
• Crawford N, Clothier H, Hodgson K, Selvaraj G, Easton M, Buttery J. Active surveillance for adverse events following immunization. Expert Rev Vaccines. 2013;13(2):265–76. doi:10.1586/14760584.2014.866895.
   PubMed Web of Science ®Google Scholar
• Thoon K, Soh S, Liew W, Gunachandran A, Tan N, Chong C, Yung CF. Active surveillance of adverse events following childhood immunization in Singapore. Vaccine. 2014;32(39):5000–05. doi:10.1016/j.vaccine.2014.07.020.
   PubMed Web of Science ®Google Scholar
• Vaudry W, Lee B, Roth A. Active hospital based surveillance for meningococcal vaccine adverse events after a community mass immunization program. Paediatr Child Health. 2002;7(suppl_A):33A–34A. doi:10.1093/pch/7.suppl_A.33Aa.
   PubMedGoogle Scholar
• WHO. Adverse event following immunization. Aide-Mémoire On Causality Assessment. [accessed on 2019 March 15]. http://www.who.int/vaccine_safety/initiative/investigation/New_aide_mem_causal_assmt.pdf.
   Google Scholar
• Alicino C, Merlano C, Zappettini S, Schiaffino S, Della Luna G, Accardo C, Gasparini R, Durando P, Icardi G. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother. 2014;11(1):91–94. doi:10.4161/hv.34360.
   PubMed Web of Science ®Google Scholar
• National Drug Authority (AIFA). Rapporto sulla sorveglianza post-marketing dei vaccini in Italia Anno 2017. [accessed on 2019 March 17]. http://www.aifa.gov.it/sites/default/files/Rapp_Vaccini_2017_0.pdf.
   Google Scholar
• Stefanizzi P, Calabrese G, Infantino V, Del Matto G, Tafuri S, Quarto M. Systematic Use of causality assessment in AEFI surveillance: a 2013-2016 pilot study in Puglia. EBMJ. 2017;12:154–58.
   Google Scholar
• Puliyel J, Naik P. Revised World Health Organization (WHO)’s causality assessment of adverse events following immunization—a critique. F1000 Research. 2018;7:243. doi:10.12688/f1000research.
   PubMedGoogle Scholar
• CDC. Licensure of a combined live attenuated measles, mumps, rubella and varicella vaccineMorbidity and Mortality Weekly Report (MMWR). 2005;54. 1212–14.
   Google Scholar
• CDC. Measles, mumps, and rubella–vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1998;47(RR–8):1–57.
   PubMedGoogle Scholar
• European Medicine Agency. Proquad. [accessed on 2019 March 17]. https://www.ema.europa.eu/en/medicines/human/EPAR/proquad.
   Google Scholar
• Jacobsen S, Ackerson B, Sy L, Tran T, Jones T, Yao J, Xie F, Cheetham TC, Saddier P. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656–61. doi:10.1016/j.vaccine.2009.05.056.
   PubMed Web of Science ®Google Scholar
• Klein N, Fireman B, Yih W, Lewis E, Kulldorff M, Ray P, Baxter R, Hambidge S, Nordin J, Naleway A, et al. Measles-Mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–e8. doi:10.1542/peds.2010-0665.
   PubMed Web of Science ®Google Scholar
• Ma S, Xiong Y, Jiang L, Chen Q. Risk of febrile seizure after measles–mumps–rubella–varicella vaccine: A systematic review and meta-analysis. Vaccine. 2015;33(31):3636–49. doi:10.1016/j.vaccine.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Marin M, Broder KR, Temte JL, Snider DE, Seward JF Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 May 7;59(RR–3). 1–12.
   PubMedGoogle Scholar
• Macartney K, Gidding H, Trinh L, Wang H, Dey A, Hull B, Orr K, McRae J, Richmond P, Gold M, et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatr. 2017;171(10):992. doi:10.1001/jamapediatrics.2017.1965.
   PubMed Web of Science ®Google Scholar
• Klopfer S, Stek J, Petrecz M, Reisinger K, Black S, Goveia M, Nicholson O, Gardner JL, Grosso AD, Brown ML, et al. Analysis of safety data in children after receiving two doses of ProQuad® (MMRV). Vaccine. 2014;32(52):7154–60. doi:10.1016/j.vaccine.2014.08.067.
   PubMed Web of Science ®Google Scholar
• WHO. Vaccine-preventable diseases: monitoring system. 2018 global summary. [accessed on 2019 March 20]. http://apps.who.int/immunization_monitoring/globalsummary/schedules.
   Google Scholar
• Puglia R. Assessorato alle politiche della salute settore assistenza territoriale prevenzione. Bollettino Ufficiale n. 124 del 12-8-2009 – verbale Commissione Regionale Vaccini n. 2/2009 dell’8 giugno. 2009. [accessed on 2019 March 22]. http://www.regione.puglia.it/documents/10192/5083710/N124_12_08_09.pdf/4da63ac5-cd29-4794-9f6c-5417081a120a.
   Google Scholar
• Ministero della Salute – Dipartimento della Sanità Pubblica e Innovazione. DGPRE 0021509-P-10/10/2012. Indicazioni in merito alla somministrazione della vaccinazione contro la varicella in età pediatrica. 2012.
   Google Scholar
• AIFA – Working Group Pediatrico. Raccomandazioni del working group pediatrico dell’AIFA in relazione all’ utilizzo dei vaccini MPRV. [accessed on 2019 March 21]. http://www.aifa.gov.it/sites/default/files/raccomandazione_vaccino_mprv_14_novembre_2011.pdf.
   Google Scholar
• Ministero della Salute. Legge n. 119 del 31 luglio 2017. Pubblicato in Gazzetta Ufficiale n. 182 del 05-08-2017. [accessed on 2019 March 23]. http://www.gazzettaufficiale.it/eli/id/2017/08/5/17G00132/sg.
   Google Scholar
• Epicentro-Istituto Superiore della Sanità. Vaccini e vaccinazioni - Copertura vaccinale in Italia. [accessed on 2019 March 20]. http://www.epicentro.iss.it/vaccini/dati_Ita#morbillo.
   Google Scholar
• Gruppo di lavoro Malinf della Regione Puglia. Bollettino delle coperture vaccinali al 31 dicembre 2017- dalla nascita all’adolescenza. [accessed on 2019 March 21]. https://www.sanita.puglia.it/documents/36126/269121/Bollettino+delle+Coperture+Vaccinali+al+31+dicembre+2017+-+dalla+nascita+all%27adolescenza/3b204405-e020-4db3-8ae4-78cb088ed15f?version=1.3&t=1524747097880.
   Google Scholar
• AIFA – Gruppo di Lavoro sull’analisi dei segnali dei vaccini. Guida alla valutazione delle reazioni avverse osservabili dopo vaccinazione. 2016. [accessed on 2019 March 24]. http://www.aifa.gov.it/sites/default/files/Guida_valutazione_reazioni_avverse_osservabili_dopo_vaccinazione_2.pdf.
   Google Scholar
• European Medical Agency. Important medical event terms list. [accessed on 2019 March 23]. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview.
   Google Scholar
• Myers T, McNeil M, Ng C, Li R, Lewis P, Cano M. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010–2015. Vaccine. 2017;35(14):1758–63. doi:10.1016/j.vaccine.2017.02.030.
   PubMed Web of Science ®Google Scholar
• Esposito S, Bianchini S, Dellepiane R, Principi N. Vaccines and Kawasaki disease. Expert Rev Vaccines. 2015;1–8.
   PubMed Web of Science ®Google Scholar
• Chung E. Vaccine allergies. Clin Exp Vaccine Res. 2014;3(1):50. doi:10.7774/cevr.2014.3.1.50.
   PubMedGoogle Scholar
• Mantadakis E, Farmaki E, Buchanan G. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 2010;156(4):623–28. doi:10.1016/j.jpeds.2009.10.015.
   PubMed Web of Science ®Google Scholar
• Vigo A, Costagliola G, Ferrero E, Noce S. Hypotonic-hyporesponsive episodes after administration of hexavalent DTP-based combination vaccine: a description of 12 cases. Hum Vaccin Immunother. 2017;13(6):1375–78. doi:10.1080/21645515.2017.1287642.
   PubMed Web of Science ®Google Scholar
• Taylor L, Swerdfeger A, Eslick G. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623–29. doi:10.1016/j.vaccine.2014.04.085.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Maruyama H, Fujimoto K, Sakakura T, Seishu S, Okuda N. Hematologic findings associated with thrombocytopenia during the acute phase of exanthem subitum confirmed by primary human herpesvirus-6 infection. J Pediatr Hematol Oncol. 2002;24(3):211–14. doi:10.1097/00043426-200203000-00010.
   PubMed Web of Science ®Google Scholar
• Tafuri S, Gallone M, Calabrese G, Germinario C. Adverse events following immunization: is this time for the use of WHO causality assessment? Expert Rev Vaccines. 2015;14(5):625–27. doi:10.1586/14760584.2015.1029460.
   PubMed Web of Science ®Google Scholar
• Gabutti G, Kuhdari P, Ferioli S, Trucchi C. Hospital admissions for seizure in Italy: a decennial retrospective analysis with a special focus on the burden in the pediatric age. Neurol Sci. 2015 Sep;36(9):1667–73. doi:10.1007/s10072-015-2230-1.
   PubMed Web of Science ®Google Scholar
• Cocchio S, Zanoni G, Opri R, Russo F, Baldo V. A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy. Hum Vaccin Immunother. 2015;12(3):651–54. doi:10.1080/21645515.2015.1101198.
   Web of Science ®Google Scholar
• Tafuri S, Fortunato F, Gallone M, Stefanizzi P, Calabrese G, Boccalini S, Martinelli D, Prato R. Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine. 2018;36(8):1072–77. doi:10.1016/j.vaccine.2018.01.018.
   PubMed Web of Science ®Google Scholar
• Sukumaran L, McNeil M, Moro P, Lewis P, Winiecki S, Shimabukuro T. Adverse events following measles, mumps, and rubella vaccine in adults reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013. Clin Infect Dis. 2015. doi:10.1093/cid/civ061.
   PubMed Web of Science ®Google Scholar
• Lei J, Balakrishnan M, Gidudu J, Zuber P. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000–2015. Vaccine. 2018;36(12):1577–82. doi:10.1016/j.vaccine.2018.02.012.
   PubMed Web of Science ®Google Scholar